How FIT2 controls liver fat and the production of artery-clogging VLDL
The role of FIT2 in VLDL assembly, hepatic triglyceride homeostasis, and lipoprotein atherogenicity
This work aims to understand how a liver protein called FIT2 controls production and composition of fat-rich VLDL particles that can raise heart disease risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project ID | NIH-11309607 on NIH RePORTER |
What this research studies
From a patient's perspective, researchers are studying a liver protein called FIT2 to learn how it helps pack triglycerides onto apoB to form VLDL particles. The team uses lab-grown liver cells and specially engineered rodent models to observe FIT2, endoplasmic reticulum processes, and lipid droplets as VLDL is built and secreted. They will use molecular experiments, imaging, and biochemical assays to measure how changes in FIT2 change VLDL size, composition, and secretion. This is preclinical laboratory and animal research, so it does not offer immediate treatments for patients.
Who could benefit from this research
Good fit: People with high blood triglycerides, fatty liver disease (NAFLD/NASH), or elevated risk of atherosclerotic cardiovascular disease would be most likely to benefit from future therapies informed by this work.
Not a fit: Patients seeking immediate clinical treatments or those with conditions unrelated to liver lipid metabolism are unlikely to receive direct benefit from this basic laboratory study.
Why it matters
Potential benefit: If successful, this work could point to new targets for lowering triglyceride-rich VLDL and reducing atherosclerosis risk.
How similar studies have performed: Previous laboratory and animal studies, including preliminary work by the investigators, suggest FIT2 influences triglyceride assembly onto apoB, but translation into human therapies is still early and unproven.
Where this research is happening
New York, United States
- New York University School of Medicine — New York, United States (Active)
Researchers
- Principal investigator: Fisher, Edward a — New York University School of Medicine
- Study coordinator: Fisher, Edward a
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.